GATX Corporation

Thank you for standing by and welcome to the Intuitive Third Quarter 2025 Earnings Release. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 1-1 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Dan Connolly, Head of Investor Relations at Intuitive. Please go ahead, Sarah.

Good afternoon, and welcome to Intuitive's third quarter earnings conference call. Joining me today are Dave Rosa, our CEO, and Jamie Samath, our CFO. Before we begin, I would like to remind you that comments on today's call may contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in our Securities and Exchange Commission filings, including our most recent 10-K filed on January 31st, 2025, and Form 10-Q filed on July 23rd, 2025. Our SEC filings can be found through our website at intuitive.com or at the SEC's website. Investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website in the events section under our investor relations page. We have posted today's press release and supplementary financial data tables to our website. Our format for this afternoon's earnings conference call is as follows. Dave will review business and operational highlights. Jamie will provide a review of our financial results and procedure highlights. I will review clinical highlights and discuss our updated financial outlook for 2025. And finally, we will host a question and answer session. With that, I'll turn it over to Dave.

Good afternoon, and thank you for joining us today. Q3 2025 was an excellent quarter for Intuitive, which strengthened worldwide procedure growth and capital placements. as well as increasing utilization across all platforms. Globally, customer interest in and adoption of DaVinci 5 expanded. Domestically, customers responded to our first full quarter of broad DaVinci 5 availability with increased demand for system upgrades and dual consoles. Internationally, we placed our first systems in Japan and Europe, with surgeons performing initial cases in those geographies. Turning to procedures. Da Vinci procedures increased by 19% and ion procedures were higher by 52%, leading to total worldwide procedure growth of 20%. Da Vinci procedure growth reflected strength in benign general surgery in the US and accretive growth in general surgery and gynecology internationally. System utilization defined as procedures per installed clinical system per quarter grew 4% for our Da Vinci multiport platforms 35% for SP, and 14% for Ion. In the first 18 months since launch, DaVinci Utilization is validating our design intent, already outpacing XI. Procedure demand has been healthy, and as DaVinci 5 catalyzed upgrades, we saw the multi-port install-based utilization ticking up to absorb that demand. This is healthy for our customers and for our company. Turning to capital, we placed 427 DaVinci systems, including 240 DaVinci 5 systems and 30 SP systems, as well as 50 Ion systems. Demand for DaVinci 5 upgrades drove strong domestic placements. We believe upgrades are an effective way for customers to expand throughput and capabilities. These capabilities include force sensing, surge in autonomy, telepresence, and various other digital tools that may lead to enhanced understanding of what great surgery looks like and further adoption of robotic-assisted surgery over time. Additionally, it is our intent to offer refurbished XI systems as part of our broader portfolio, which will help expand access in certain geographies and sites of care. Internationally, da Vinci placements reflected ongoing external dynamics in Japan, China, and the UK, offset by broad-based strength in other international markets. Customer adoption of our products resulted in strong financial performance reflected in 23% revenue growth, and combined with strong operating discipline, 30% earnings growth. Jamie will provide further details on procedures, systems, and finances later in the call. Last month, we hosted our 10th annual Intuitive360 User Conference in San Diego. where more than 1,100 healthcare professionals representing over 450 institutions from around the world gathered to exchange ideas and shape the future of patient care. Customers remained acutely focused on improving patient outcomes, reducing clinical and operational variation, driving efficiency, and increasing access to minimally invasive care. More than 30 institutions presented their own clinical and financial outcomes data which further validated the value of our three existing platforms. I had the opportunity to sit down with multiple customers and dive deep into their robotic programs, including the impact of DaVinci 5 and potential fleet standardization, site of care dynamics, and their overall lung cancer programs. I was encouraged to see the depth of their data and analyses and how these customers were able to quantify the impact of their intuitive programs on aspects of the quintuple aim. Domestically, while we remain in limited launch with force feedback instrumentation, we are working closely with customers to support their analyses of the impact of force feedback on clinical outcomes and learning progression. I am encouraged by early feedback and excited to see where some of these studies are leading. Dan will highlight some of this data later in the call. Across all of our platforms, we consistently upgrade capability and reliability through software and hardware releases. In Q3, we received FDA 510 clearance for the first in a series of software updates for DaVinci 5. With the addition of network central configuration management, we are now able to deploy updates remotely, which significantly streamlines workflow for both our customers and Intuitive. This release also includes the visual representation of force through force gauge and focus mode, which enables in-console video replay and viewing registration and manipulation of 3D models. These features enhance surgeon awareness and interoperative decision making. You will see us continue to make improvements to the platform that advance our vision of delivering real-time insights at the point of care to support clinical efficiency with the aim of improving outcomes. Internationally, we placed our first nine systems in Japan and Europe and have received positive early feedback. We look forward to engaging customers as they continue to evaluate DaVinci 5. Our DaVinci SinglePort platform made further progress in Q3. Procedures increased 91%, led by ongoing growth in Korea, continued early progress in other international markets, and initial domestic use of the SP stapler in colorectal and thoracic procedures. At 360, I had a conversation with a longtime DaVinci thoracic surgeon about his initial experience using SP on about 40 patients. He was enthusiastic both about the reduction in length of stay and also his first few cases of using the SP stapler. I share his enthusiasm about these early results and look forward to seeing more data from colorectal and thoracic procedures as our launch progresses. Recent 510 clearances support several advanced features. including sensitive Firefly and various control algorithms aimed at further improving SP stapler usability. Since we last spoke with you on our Q2 call, we have completed US regulatory submissions for nipple sparing mastectomy and other general surgery procedures. We look forward to updating you on these efforts on future calls. Turning to ION, worldwide procedures grew 52% to just under 38,000. We are now delivering ION's differentiated value at scale, providing precise and individualized patient-specific navigation plans, using AI to segment each CT scan and plan the biopsy trajectory. This quarter, we received FDA clearance for a significant software release that improves workflow and imaging options, including upgraded system software that uses real-time AI to enable even more precise airway navigation and tomosynthesis integration, broadening the suite of imaging offerings when combined CT is not available. In closing, we are committed to our 2025 priorities. First, focusing on the full launch of DaVinci 5, its regional clearances and follow-on feature releases. Second, we'll pursue increased adoption of our focused procedures by country through training, commercial activities, and market access efforts. Third, we'll drive continued progress in building industrial scale, product quality, and manufacturing optimization. And finally, we'll focus on excellence and availability of our digital tools. Looking ahead, by virtue of our focus on patients, our alignment with customers in pursuit of the quintuple aim, our investments in both industrial scale and innovation, and our commercial excellence, We are well positioned, operationally and financially, to further increase value to patients, physicians, hospitals, and payers globally. With that, I'll turn the time over to Jamie to take you through our business and finances in greater detail. Good afternoon.